Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.
Type:
Application
Filed:
September 21, 2015
Publication date:
March 24, 2016
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Ivan McConnell, Peter Fitzgerald, Phillip Lowry, Elouard Benchikh
Abstract: The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1.
Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
Type:
Grant
Filed:
October 30, 2013
Date of Patent:
July 14, 2015
Assignee:
RANDOX LABORATORIES LIMITED
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
December 9, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
Type:
Application
Filed:
October 30, 2013
Publication date:
September 25, 2014
Applicant:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.
Type:
Application
Filed:
February 19, 2014
Publication date:
August 28, 2014
Applicant:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.
Type:
Application
Filed:
February 21, 2014
Publication date:
August 28, 2014
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
Abstract: The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.
Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
May 27, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Andrew Philip Lowry, Ivan McConnell, Peter Stephen Fitzgerald
Abstract: The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse.
Type:
Grant
Filed:
February 1, 2011
Date of Patent:
March 18, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Stephen Peter Fitzgerald, Robert Ivan McConnell, Philip Andrew Lowry, Elouard Benchikh
Abstract: The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens.
Type:
Grant
Filed:
March 15, 2012
Date of Patent:
December 31, 2013
Assignee:
Randox Laboratories Limited
Inventors:
Peter Stephen Fitzgerald, Ivan Robert McConnell, Philip Andrew Lowry, Elouard Benchikh
Abstract: A method for ‘ruling out’ acute myocardial infarction (AMI) in a subject presenting with chest pain expected to be cardiac in nature. The method includes a) recording an Electrocardiography (ECG) reading from said subject, b) determining the amount of Heart-type Fatty acid binding protein (H-FABP) and cardiac Troponin T (cTnT) in a sample from said subject, c) comparing the results from b) to reference values for ruling out an acute Myocardial Infarction in a subject, and d) based on the results from steps a)-c) either ‘ruling out’ or ‘ruling in’ a diagnosis of acute Myocardial Infarction in said subject.
Abstract: The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies.
Type:
Application
Filed:
December 20, 2011
Publication date:
November 21, 2013
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Stephen Peter Fitzgerald, Elouard Benchikh, Ivan McConnell, Philip Andrew Lowry
Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
September 10, 2013
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
Abstract: The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity.
Abstract: The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones.
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Application
Filed:
August 14, 2012
Publication date:
August 1, 2013
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Stephen Peter Fitzgerald, Paul John Innocenzi, Elouard Benchikh, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Application
Filed:
August 14, 2012
Publication date:
March 14, 2013
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Stephen Peter Fitzberald, Ivan Robert McConnell, Paul John Innocenzi, Elouard Benchikh, Philip Andrew Lowry
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Application
Filed:
August 14, 2012
Publication date:
March 14, 2013
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
Type:
Application
Filed:
June 18, 2012
Publication date:
December 20, 2012
Applicant:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Andrew Philip Lowry, Ivan McConnell, Peter Stephen Fitzgerald